Review of the reported measures of clinical validity and clinical utility as arguments for the implementation of pharmacogenetic testing: A case study of statin-induced muscle toxicity. Jansen, M. E., Rigter, T., Rodenburg, W., Fleur, T. M. C., Houwink, E. J. F., Weda, M., & Cornel, M. C. (2017). Frontiers in Pharmacology, 8, 555.

Policy Making in Newborn Screening Needs a Structured and Transparent Approach. Jansen ME, Lister KJ, van Kranen HJ, Cornel MC. Frontiers in Public Health. doi: 10.3389/fpubh.2017.00053

International differences in the evaluation of conditions for newborn bloodspot screening: a review of scientific literature and policy documents. Jansen ME, Metternick-Jones SC, Lister K. Eur J Hum Genet advance online publication, November 16, 2016; doi:10.1038/ejhg.2016.126

PhD thesis: Implementing Genetic Tests - Infertility and Newborn Bloodspot Screening

Potential protective effect of a G>A SNP in the 3'UTRE of HLA-A for Chlamydia trachomatis sympotmatology and severity of infection. Jansen ME, Brankovic I, Spaargaren J, Ouburg S, Morré SA. 2016. Pathogens and Disease 2016: 74 (2). DOI: 10.1093/femspd/ftv116

Report: Access to Personalised Medicine for PDAC-patients. COST Action EU Pancreas.

An Index of Barriers for the Implementation of Personalised Medicine and Pharmacogenomics in Europe. Horgan D, Jansen M, Leyens L, Lal JA, Sudbrak R, Hackenitz E, BuBhoff U, Ballensiefen W, Brand A. Public Health Genomics 2014: 17. DOI:10.1159/000368034